{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:54:04Z","timestamp":1777452844222,"version":"3.51.4"},"reference-count":15,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In China, the clinical management of chronic hepatitis B (CHB) is complicated by the use of various-nucleoside\/nucleotide analogue (NUC) regimens in treatment-naive patients, including NUCs with low genetic barriers to resistance, with\/without add-on therapy and de novo NUC combinations. This longitudinal observational study therefore investigated the real-world clinical management and efficacy of NUC therapy in treatment-naive CHB patients in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Treatment-naive CHB patients initiated on NUC therapy were enrolled from 63 hospitals in tier-2 Chinese cities. Demographic and treatment-specific data were collected, with the objective of reporting real-world treatment patterns and comparing the effectiveness of entecavir (ETV) treatment and lamivudine (LAM)-based treatment. We herein report the first-year data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>3,408 NUC-naive patients were enrolled and treated with NUCs (53% ETV, 18% LAM-based, 29% other). Overall, 6.6% of patients modified their initial treatment, with ETV having lower rates of treatment modification than other major NUCs ( P&lt;0.05). At week 52, the virological response rate was higher with ETV than with LAM-based treatment (77.0% versus 61.4%; P&lt;0.0001). LAM-based treatment was associated with a higher probability of virological breakthrough and genotypic resistance (21.4% and 19.6%, respectively) than ETV (1.6% and 0.1%, respectively; P&lt;0.0001). Treatment-related adverse events or serious adverse events were uncommon.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this nationwide observational study, more than 50% of patients with CHB in tier-2 city hospitals in China initially received ETV therapy. Consistent with clinical trial results, ETV was more effective than LAM-based treatments in a real-world setting, with the rate of treatment modification being relatively low in ETV-treated patients. ClinicalTrials.gov Identifer: NCT01726439.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp3205","type":"journal-article","created":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T10:34:49Z","timestamp":1510137289000},"page":"201-209","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Real-World Evidence for Nucleoside\/Nucleotide Analogues in a 5-Year Multicentre Study of Antiviral-Naive Chronic Hepatitis B Patients in China: 52-Week Results"],"prefix":"10.1177","volume":"23","author":[{"given":"Jidong","family":"Jia","sequence":"first","affiliation":[{"name":"Beijing Friendship Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Tang","sequence":"additional","affiliation":[{"name":"West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Ning","sequence":"additional","affiliation":[{"name":"Affiliated Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaji","family":"Jiang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Fujian Medical University, Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoguang","family":"Dou","sequence":"additional","affiliation":[{"name":"Shengjing Hospital of China Medical University, Shenyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Sixth People's Hospital of Shenyang, Shenyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuqin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Hepatology Hospital of Jilin Province, Changchun, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Shang","sequence":"additional","affiliation":[{"name":"Henan Provincial People's Hospital, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Lu","sequence":"additional","affiliation":[{"name":"The Second People's Hospital of Tianjin, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinong","family":"Ye","sequence":"additional","affiliation":[{"name":"The First People's Hospital of Foshan, Foshan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[{"name":"GCP ClinPlus Co., Ltd, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingshu","family":"Li","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingyan","family":"Bo","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenzhong","family":"Tan","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the EVOLVE Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2017,4,1]]},"reference":[{"key":"bibr1-IMP3205","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.1.65"},{"key":"bibr2-IMP3205","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyh339"},{"key":"bibr3-IMP3205","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.016"},{"key":"bibr4-IMP3205","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.08.048"},{"key":"bibr5-IMP3205","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12835"},{"key":"bibr6-IMP3205","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26885"},{"key":"bibr7-IMP3205","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-010-9243-x"},{"key":"bibr8-IMP3205","first-page":"88","volume":"19","author":"Yu J.H.","year":"2011","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"bibr9-IMP3205","first-page":"13","volume":"19","author":"Chinese Society of Hepatology and Chinese Society of Infectious Diseases.","year":"2011","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"bibr10-IMP3205","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"bibr11-IMP3205","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9675-4"},{"key":"bibr12-IMP3205","unstructured":"Jia J., Hou J., Han T. CR-HepB: A new registry system for documenting and analyzing the demography, virology and medicine treatments of hepatitis B in China. AASLD LiverLearning\n                      \u00ae\n                      2013;35821. (Accessed 13 February 2018.) Available from https:\/\/liverlearning.aasld.org\/aasld\/2013\/thelivermeeting\/35821\/jidong.jia.cr-hepb.a.new.registry.system.for.documenting.and.analyzing.the.html."},{"key":"bibr13-IMP3205","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.05.037"},{"key":"bibr14-IMP3205","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12115"},{"key":"bibr15-IMP3205","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3851\/IMP2573","volume":"19","author":"Marcellin P.","year":"2014","journal-title":"Antivir Ther"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3205","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:52:27Z","timestamp":1777380747000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP3205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,1]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.3851\/IMP3205"],"URL":"https:\/\/doi.org\/10.3851\/imp3205","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,1]]}}}